| scholarly article | Q13442814 |
| P2093 | author name string | Igor Grant | |
| B Rael Cahn | |||
| P2860 | cites work | Cannabinoid receptor localization in brain | Q24558751 |
| Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors | Q24642509 | ||
| Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants | Q24685540 | ||
| The effects of cannabinoids on the brain | Q28137626 | ||
| Cannabinoids control spasticity and tremor in a multiple sclerosis model | Q28138564 | ||
| Cannabinoid receptors and pain | Q28143655 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats | Q28271665 | ||
| 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain | Q28290395 | ||
| Trick or treat from food endocannabinoids? | Q28292565 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation | Q28372120 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| Modulation of anxiety through blockade of anandamide hydrolysis | Q29615902 | ||
| Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data | Q30807024 | ||
| Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies | Q33215661 | ||
| Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity | Q33695254 | ||
| Towards cannabinoid drugs--revisited. | Q33906007 | ||
| Abstinence symptoms during withdrawal from chronic marijuana use. | Q33928980 | ||
| Antineoplastic Activity of Cannabinoids2 | Q33955179 | ||
| Tetrahydrocannabinol and endocannabinoids in feeding and appetite | Q33960904 | ||
| Therapeutic potential of cannabinoids in CNS disease | Q33964721 | ||
| Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia | Q34064876 | ||
| An endogenous cannabinoid (2-AG) is neuroprotective after brain injury | Q34093755 | ||
| Cannabinoids in clinical practice | Q34127411 | ||
| Therapeutic aspects of cannabis and cannabinoids | Q34130996 | ||
| Cannabinoids for gastrointestinal diseases: potential therapeutic applications | Q34169100 | ||
| Cannabis and the brain | Q34199483 | ||
| Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study | Q34220050 | ||
| Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 | ||
| Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor | Q34358410 | ||
| Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. | Q34420730 | ||
| Pharmacological actions and therapeutic uses of cannabis and cannabinoids. | Q34434597 | ||
| Cannabinoids: a real prospect for pain relief? | Q34489886 | ||
| Established and potential therapeutic applications of cannabinoids in oncology | Q34531841 | ||
| Cannabinoids: potential anticancer agents | Q34542671 | ||
| Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial | Q34543217 | ||
| 60- and 72-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: cognitive and language assessment | Q34544172 | ||
| Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study | Q34550419 | ||
| The brain's own marijuana | Q34553408 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Cannabinoid addiction: behavioral models and neural correlates. | Q34616145 | ||
| Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression | Q34673005 | ||
| Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. | Q34748762 | ||
| Cannabinoids and multiple sclerosis | Q34786839 | ||
| Cannabinoids in the treatment of glaucoma | Q34786852 | ||
| The endocannabinoid system: function in survival of the embryo, the newborn and the neuron | Q34978245 | ||
| Cannabinoids and neuroinflammation | Q35046205 | ||
| Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. | Q35684044 | ||
| Cannabinoids and glaucoma | Q35748271 | ||
| Hypothesis: cannabinoid therapy for the treatment of gliomas? | Q35846509 | ||
| Cannabinoids as neuroprotective agents in traumatic brain injury | Q35849613 | ||
| The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans | Q35859623 | ||
| Review of the validity and significance of cannabis withdrawal syndrome | Q35932862 | ||
| Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. | Q35938826 | ||
| Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors. | Q35948596 | ||
| Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals | Q36466255 | ||
| Management of anorexia-cachexia associated with cancer and HIV infection. | Q36704153 | ||
| Cannabinoids cool the intestine | Q36837926 | ||
| The endogenous cannabinoid system protects against colonic inflammation | Q37370275 | ||
| The analgesic properties of delta-9-tetrahydrocannabinol and codeine | Q39336497 | ||
| Pain measurements and side effect profile of the novel cannabinoid ajulemic acid | Q39366716 | ||
| Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis | Q44929830 | ||
| Prenatal marijuana and alcohol exposure and academic achievement at age 10. | Q44941195 | ||
| Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide | Q45081681 | ||
| Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock | Q45108255 | ||
| Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease | Q45111716 | ||
| Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens | Q46504862 | ||
| Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. | Q47282573 | ||
| Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. | Q47360477 | ||
| Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response | Q48171307 | ||
| Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity | Q48398761 | ||
| Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors | Q48664473 | ||
| Involvement of CB1 cannabinoid receptors in emotional behaviour. | Q51055974 | ||
| Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. | Q51985298 | ||
| Effects of Moderate and High Doses of Marihuana on Thermal Pain: A Sensory Decision Theory Analysis | Q52101107 | ||
| Changes in aggressive behavior during withdrawal from long-term marijuana use. | Q55033076 | ||
| Cannabinoid CB1 Receptor Expression in Rat Spinal Cord | Q56827591 | ||
| Inhalation marijuana as an antiemetic for cancer chemotherapy | Q68041813 | ||
| Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model | Q68297258 | ||
| Delta-9-THC in the treatment of spasticity associated with multiple sclerosis | Q69821028 | ||
| Evaluation of intramuscular levonantradol and placebo in acute postoperative pain | Q70189996 | ||
| Effect of dronabinol on nutritional status in HIV infection | Q70473081 | ||
| Effects of topical anandamides on intraocular pressure in normotensive rabbits | Q71094610 | ||
| Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine | Q72124376 | ||
| Suppression of experimental autoimmune encephalomyelitis by cannabinoids | Q72535664 | ||
| Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis | Q72861640 | ||
| Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis | Q72871143 | ||
| A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy | Q72890308 | ||
| Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2 | Q73289475 | ||
| Marijuana withdrawal among adults seeking treatment for marijuana dependence | Q73312718 | ||
| Reading and language in 9- to 12-year olds prenatally exposed to cigarettes and marijuana | Q73452306 | ||
| CB1 cannabinoid receptor induction in experimental stroke | Q74159405 | ||
| CB2 cannabinoid receptor-mediated peripheral antinociception | Q74403213 | ||
| SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset | Q74582466 | ||
| Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial | Q39373693 | ||
| Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. | Q39549838 | ||
| Analgesic Effect of Delta‐9‐Tetrahydrocannabinol | Q39589738 | ||
| Cannabinoid pharmacology | Q39741984 | ||
| Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol | Q40139775 | ||
| A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia | Q40674304 | ||
| Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia | Q40706673 | ||
| Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal | Q40890918 | ||
| HIV wasting syndrome: treatment update | Q41751382 | ||
| De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. | Q41775676 | ||
| Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain | Q42451047 | ||
| Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period | Q42475353 | ||
| Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. | Q42513159 | ||
| Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors | Q42549099 | ||
| An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis | Q42634202 | ||
| The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. | Q42686860 | ||
| SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats | Q43339764 | ||
| Phase 1 trial of levonantradol in chemotherapy-induced emesis | Q43471900 | ||
| Conduct problems and early cannabis initiation: a longitudinal study of gender differences | Q43545961 | ||
| Critical role of the endogenous cannabinoid system in mouse pup suckling and growth | Q43653896 | ||
| Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters | Q43744072 | ||
| Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration | Q43752352 | ||
| Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret | Q43770448 | ||
| Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation | Q43811705 | ||
| Safety, tolerability, and efficacy of orally administered cannabinoids in MS. | Q43993945 | ||
| Trends in neuroprotection. | Q44023215 | ||
| The endogenous cannabinoid system controls extinction of aversive memories | Q44085607 | ||
| Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens | Q44299680 | ||
| Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 | ||
| Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response | Q44465384 | ||
| Cannabinoids inhibit neurodegeneration in models of multiple sclerosis | Q44522438 | ||
| Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial | Q44579299 | ||
| Anandamide hydrolysis: a new target for anti-anxiety drugs? | Q44646866 | ||
| Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures | Q44740877 | ||
| P433 | issue | 2-4 | |
| P921 | main subject | endocannabinoids | Q10483908 |
| P304 | page(s) | 185-199 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Clinical neuroscience research | Q27721154 |
| P1476 | title | Cannabis and endocannabinoid modulators: Therapeutic promises and challenges | |
| P478 | volume | 5 |
| Q34581675 | Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance |
| Q38040442 | Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention |
| Q34718132 | Anandamide reduces intracellular Ca2+ concentration through suppression of Na+/Ca2+ exchanger current in rat cardiac myocytes |
| Q35103574 | Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities |
| Q34402180 | Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies |
| Q36844731 | Cannabinoids Occlude the HIV-1 Tat-Induced Decrease in GABAergic Neurotransmission in Prefrontal Cortex Slices. |
| Q98288614 | Cannabinoids, Endocannabinoids and Sleep |
| Q37826693 | Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation |
| Q28292025 | Distribution of CB2 cannabinoid receptor in adult rat retina |
| Q41952535 | Electrophysiological effects of anandamide on rat myocardium |
| Q64111076 | Endocannabinoid Metabolome Characterization of Milk from Guatemalan Women Living in the Western Highlands |
| Q57158120 | Endocannabinoid Metabolome Characterization of Transitional and Mature Human Milk |
| Q48347204 | Further Evidence for the Neuroplastic Role of Cannabinoids: A Study in Organotypic Hippocampal Slice Cultures |
| Q34987458 | Low omega-6 vs. low omega-6 plus high omega-3 dietary intervention for chronic daily headache: protocol for a randomized clinical trial |
| Q45232572 | Prevalence of medical marijuana use in California, 2012. |
| Q36404379 | Role of cannabinoids in the regulation of bone remodeling |
| Q37818137 | Role of cannabinoids in the treatment of pain and (painful) spasticity |
| Q34393890 | The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease |
| Q42500348 | Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. |
Search more.